Cannabics Pharmaceuticals Receives Cannabinoid R&D Lab Certification in Israel

BETHESDA, MD--(Marketwired - Oct 20, 2014) - Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has received Government Certification from the Ministry of Health in Israel for the establishment of an advanced R&D laboratory dedicated to medical research in the field of cannabinoid science.

The stated goal of Cannabics Pharmaceuticals is to be one of the first and few companies in the world to commercialize indication specific and clinically tested cannabis-based medical products. In Accordance with this goal, Cannabics Pharmaceuticals is currently in advanced preparations for the launch of a series of rigorous and controlled clinical studies in leading medical centers in Israel where the Company's R&D division is strategically located.

Their new cutting edge laboratory is designed to employ novel technologies for the development of innovative cannabinoid based therapies for a range of debilitating ailments.

Dr. Zohar Koren, CEO, stated, "The exciting scientific field of cannabinoid research has been largely neglected throughout most of the 20^th century due to a total ban on this field of research. Thus, the available scientific knowledge regarding active cannabinoids and their mechanisms of action in various disease pathways is dramatically lacking in comparison to other therapeutic fields. There is a huge space of uncharted territory to explore with regards to the potential therapeutic roles of this class of compounds for diverse indications."

The company is especially interested in the development of cannabinoid-based anti-Cancer therapies.

"The unique properties of active cannabinoids as tumor cell proliferation inhibitors and apoptosis inducers has been known for decades, however this field has never received the appropriate scientific attention it deserves as a potential source for anti-cancer therapies," commented Dr. Eyal Ballan, Chief Technology Officer. "Our new and expansive laboratory will enable us to perform our advanced research program in this field."

About Cannabics Pharmaceuticals, Inc.

Cannabics Pharmaceuticals, Inc. is an emerging drug development company focused on the development and commercialization of advanced drugs, therapies, food supplements and administration routes based on the wide range of active ingredients found in diverse and unique strains of the Cannabis plant. Cannabics' current flagship product is CANNABICS SR -- an IP pending medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Cannabics' proprietary SR technology has shown in observational studies the ability to provide 10-12 hours of steady state beneficial therapeutic effects profile, and thus allows for a convenient oral once-per-day dosing regimen of medical cannabis for patients. Cannabics is now preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory pathways, while simultaneously preparing to launch a series of formal clinical studies in order to establish the unique medical benefits of its products for patients suffering from various indications.

For more information, visit www.cannabics.com

DISCLAIMER:

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 15th, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.